- Home
- / Innocan Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Innocan Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.2
2024-10-29
Market Capitalization
$65.7 M
2024-10-29
Revenue
$26.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.0K | 196.0K | 2.6M | 13.7M | 29.4M | 26.6M | ||
| Cost of goods sold | 5.0K | 32.0K | 417.0K | 1.7M | 3.3M | 2.6M | ||
| Gross profit | 3.0K | 164.0K | 2.1M | 12.0M | 26.2M | 24.0M | ||
| Gross profit margin, % | 37.5% | 83.7% | 83.7% | 87.7% | 89.0% | 90.1% | ||
| Operating expense total | 1.2M | 2.7M | 4.5M | 7.4M | 7.9M | 15.5M | 27.4M | 25.2M |
| Depreciation and amortization | 23.0K | 40.0K | 43.0K | 35.0K | 42.0K | |||
| EBITDA | (1.2M) | (2.7M) | (4.5M) | (7.2M) | (5.8M) | (3.5M) | (1.2M) | (1.2M) |
| EBITDA margin, % | -55775.0% | -3685.2% | -225.7% | -25.7% | -4.2% | -4.6% | ||
| EBIT | (1.2M) | (2.8M) | (4.5M) | (7.3M) | (5.8M) | (3.5M) | (1.2M) | 58.0K |
| EBIT margin, % | -56275.0% | -3707.1% | -227.0% | -25.5% | -4.2% | 0.2% | ||
| Interest income | 2.8M | 2.2M | ||||||
| Interest expense | 26.0K | 334.0K | 5.2M | 2.3M | 2.0K | 258.0K | 49.0K | 3.0K |
| Pre tax profit | (1.2M) | (3.3M) | (10.0M) | (10.1M) | (3.9M) | (4.0M) | 919.0K | 85.0K |
| Income tax expense | 1.0K | 214.0K | 1.2M | 426.0K | ||||
| Net Income | (1.2M) | (3.3M) | (10.0M) | (10.1M) | (3.9M) | (4.2M) | (262.0K) | (341.0K) |